Table 3.
Factors associated with the risk of poor outcome (non-healing ulcers)
| Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|
| OR (95% CI) | P | OR (95% CI) | P | |
| Male sex | 1.01 (0.61–1.70) | 0.959 | – | – |
| Age at the diagnosis of BS > 35 years | 1.06 (0.63–1.77) | 0.833 | – | – |
| Onset of BS < 7 years | 1.39 (0.85–2.27) | 0.190 | – | – |
| Intestinal symptoms | 1.08 (0.64–1.82) | 0.766 | – | – |
| Endoscopic characteristics | – | – | ||
| Location (ileocecal and colorectum) | 2.58 (1.63–4.07) | 0.000 | 7.10 (1.81–27.86) | 0.005 |
| Number, ≥ 3 | 1.21 (0.72–2.04) | 0.463 | – | – |
| Size, > 1 cm | 1.68 (1.02–2.76) | 0.049 | 3.15 (0.91–10.84) | 0.070 |
| Lab parameters | ||||
| WBC > 6.4, × 109/L | 1.56 (0.92–2.66) | 0.093 | – | – |
| Hb < 123, g/L | 1.81 (1.05–3.11) | 0.026 | – | – |
| ESR > 24, mm/h | 2.85 (1.54–5.28) | 0.000 | 5.97 (1.73–20.53) | 0.005 |
| CRP > 44, mg/L | 1.94 (1.19–3.17) | 0.014 | – | – |
| Positive FOBT+ | 1.16 (0.64–2.09) | 0.629 | – | – |
| Positive T-SPOT | 0.56 (0.22–1.39) | 0.164 | 0.25 (0.05–1.35) | 0.107 |
| HBV-DNA | 0.95 (0.30–3.05) | 1.000 | – | – |
| Treatment | – | – | ||
| Biologics | 0.30 (0.17–0.54) | 0.000 | – | – |
| IFX therapy# | 0.24 (0.12–0.50) | 0.000 | 0.18 (0.04–0.85) | 0.031 |
| Poor compliance | 3.95 (2.35–6.62) | 0.000 | 8.56 (1.91–38.26) | 0.005 |
+FOBT: fecal occult blood test
#IFX therapy was administrated at 0,2, and 6 weeks (intravenous), and then maintained with the same dosage of IFX every 8 weeks